Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 181 to 184 of 184 entries
Sorted by: Best Match Show Resources per page
High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lin L, Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, Reiter RE.
PMID: 33219015
Clin Cancer Res. 2021 Mar 01;27(5):1505-1515. doi: 10.1158/1078-0432.CCR-20-2293. Epub 2020 Nov 20.

PURPOSE: The use of high-dose per fraction radiotherapy delivered as stereotactic body radiotherapy is a standard of care for prostate cancer. It is hypothesized that high-dose radiotherapy may enhance or suppress tumor-reactive immunity. The objective of this study was...

Cite
Lin L, Kane N, Kobayashi N, et al. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. Clin Cancer Res. 2020;27(5):1505-1515doi: 10.1158/1078-0432.CCR-20-2293.
Lin, L., Kane, N., Kobayashi, N., Kono, E. A., Yamashiro, J. M., Nickols, N. G., & Reiter, R. E. (2021). High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(5), 1505-1515. https://doi.org/10.1158/1078-0432.CCR-20-2293
Lin, Lin, et al. "High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,5 (2021): 1505-1515. doi: https://doi.org/10.1158/1078-0432.CCR-20-2293
Lin L, Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, Reiter RE. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. Clin Cancer Res. 2021 Mar 01;27(5):1505-1515. doi: 10.1158/1078-0432.CCR-20-2293. Epub 2020 Nov 20. PMID: 33219015.
Copy Download .nbib Format: NLM
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials.

Prostate cancer and prostatic diseases

Jiang T, Markovic D, Patel J, Juarez JE, Ma TM, Shabsovich D, Nickols NG, Reiter RE, Elashoff D, Rettig MB, Zaorsky NG, Spratt DE, Kishan AU.
PMID: 34400799
Prostate Cancer Prostatic Dis. 2021 Aug 16; doi: 10.1038/s41391-021-00432-2. Epub 2021 Aug 16.

BACKGROUND: While multiple randomized trials have evaluated the benefit of radiation therapy (RT) dose escalation and the use and prolongation of androgen deprivation therapy (ADT) in the treatment of prostate cancer, few studies have evaluated the relative benefit of...

Cite
Jiang T, Markovic D, Patel J, et al. Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. Prostate Cancer Prostatic Dis. 2021;doi: 10.1038/s41391-021-00432-2.
Jiang, T., Markovic, D., Patel, J., Juarez, J. E., Ma, T. M., Shabsovich, D., Nickols, N. G., Reiter, R. E., Elashoff, D., Rettig, M. B., Zaorsky, N. G., Spratt, D. E., & Kishan, A. U. (2021). Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. Prostate cancer and prostatic diseases, . https://doi.org/10.1038/s41391-021-00432-2
Jiang, Tommy, et al. "Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials." Prostate cancer and prostatic diseases vol. (2021). doi: https://doi.org/10.1038/s41391-021-00432-2
Jiang T, Markovic D, Patel J, Juarez JE, Ma TM, Shabsovich D, Nickols NG, Reiter RE, Elashoff D, Rettig MB, Zaorsky NG, Spratt DE, Kishan AU. Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. Prostate Cancer Prostatic Dis. 2021 Aug 16; doi: 10.1038/s41391-021-00432-2. Epub 2021 Aug 16. PMID: 34400799.
Copy Download .nbib Format: NLM
The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5xFAD APP/PS1 Mouse Model.

Frontiers in molecular neuroscience

Forest KH, Taketa R, Arora K, Todorovic C, Nichols RA.
PMID: 33912008
Front Mol Neurosci. 2021 Apr 12;14:576038. doi: 10.3389/fnmol.2021.576038. eCollection 2021.

Alzheimer's disease (AD) is the most common cause of dementia in the aging population. Evidence implicates elevated soluble oligomeric Aβ as one of the primary triggers during the prodromic phase leading to AD, effected largely via hyperphosphorylation of the...

Cite
Forest KH, Taketa R, Arora K, et al. The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5xFAD APP/PS1 Mouse Model. Front Mol Neurosci. 2021;14:576038doi: 10.3389/fnmol.2021.576038.
Forest, K. H., Taketa, R., Arora, K., Todorovic, C., & Nichols, R. A. (2021). The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5xFAD APP/PS1 Mouse Model. Frontiers in molecular neuroscience, 14576038. https://doi.org/10.3389/fnmol.2021.576038
Forest, Kelly H, et al. "The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5xFAD APP/PS1 Mouse Model." Frontiers in molecular neuroscience vol. 14 (2021): 576038. doi: https://doi.org/10.3389/fnmol.2021.576038
Forest KH, Taketa R, Arora K, Todorovic C, Nichols RA. The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5xFAD APP/PS1 Mouse Model. Front Mol Neurosci. 2021 Apr 12;14:576038. doi: 10.3389/fnmol.2021.576038. eCollection 2021. PMID: 33912008; PMCID: PMC8075567.
Copy Download .nbib Format: NLM
Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (.

Prion

Nichols TA, Nicholson EM, Liu Y, Tao W, Spraker TR, Lavelle M, Fischer J, Kong Q, VerCauteren KC.
PMID: 34913829
Prion. 2021 Dec;15(1):207-215. doi: 10.1080/19336896.2021.1982333.

Chronic wasting disease (CWD) continues to spread in both wild and captive cervid herds in North America and has now been identified in wild reindeer and moose in Norway, Finland and Sweden. There is limited knowledge about the variety...

Cite
Nichols TA, Nicholson EM, Liu Y, et al. Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (. Prion. 2021;15(1):207-215doi: 10.1080/19336896.2021.1982333.
Nichols, T. A., Nicholson, E. M., Liu, Y., Tao, W., Spraker, T. R., Lavelle, M., Fischer, J., Kong, Q., & VerCauteren, K. C. (2021). Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (. Prion, 15(1), 207-215. https://doi.org/10.1080/19336896.2021.1982333
Nichols, Tracy A, et al. "Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (." Prion vol. 15,1 (2021): 207-215. doi: https://doi.org/10.1080/19336896.2021.1982333
Nichols TA, Nicholson EM, Liu Y, Tao W, Spraker TR, Lavelle M, Fischer J, Kong Q, VerCauteren KC. Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (. Prion. 2021 Dec;15(1):207-215. doi: 10.1080/19336896.2021.1982333. PMID: 34913829.
Copy Download .nbib Format: NLM
Showing 181 to 184 of 184 entries